Reading KEQU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KEQU free→Reading KEQU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KEQU free→QuarterlyIQ Insights · KEQU
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On March 11, 2026, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition On December 10, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Termination of a Material Definitive Agreement. On December 4, 2025, the Company completed the Seller Note Repayment. The Seller Notes were entered into on November 1, 2024 by and between the Company and each of Richard A. Peters, William F. Peters, Rita Peters Revocable Trust, and any amendments thereto, Richard A. Peters Revocable Trust, and any amendments thereto, Karan A. Peters Revocable Trust, William F. Peters 2023 Irrevocable Trust dated December 20, 2023, and any amendments thereto,…
Entry into a Material Definitive Agreement. On December 4, 2025, Kewaunee Scientific Corporation (the "Company") entered into a First Amendment to Loan Agreement (the "First Amendment") with PNC Bank, National Association ("PNC"). The First Amendment amends the Loan Agreement, dated as of November 1, 2024 (the "Loan Agreement"), between the Company and PNC to, among other things, (i) permit the Company to repay in full the outstanding principal balances of the subordinated seller notes issued…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2025, the Board of Directors (the "Board") of Kewaunee Scientific Corporation (the "Company") appointed J. Jette Campbell to serve as a member of the Board, effective immediately. Mr. Campbell will hold office as a Class II director, for a term expiring at the Company's annual meeting of stockholders to be held in 2027 and thereaft…
Results of Operations and Financial Condition On September 10, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition On June 25, 2025, Kewaunee Scientific Corporation issued a press release announcing financial results for its fourth quarter and its fiscal year ended April 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
Other Events On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the "Company") amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended (the "Program"), which does not have a specified expiration date. The Program, as of the end of day…
Results of Operations and Financial Condition On March 12, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.